๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

23 recruiting trials

for Ocular Myasthenia Gravis

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study NCT04182984n/a1 site๐Ÿ“ Xi'an Tang-Du Hospital ยท Tests: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil) Universal Chimeric Antigen Receptor T-Cell ๏ผˆUCAR T-cell๏ผ‰ Therapy Targeting CD19/B Cell Maturation Antigen ๏ผˆCD19/BCMA๏ผ‰ in Patients With r/r Neurological Autoimmune Diseases NCT06939166EARLY Phase 11 site๐Ÿ“ Tianjin Tianjin Huanhu Hospital ยท Tests: UCAR T-cell Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844NA1 site๐Ÿ“ Liรจge Centre Hospitalier Universitaire de Liege ยท Tests: Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT), The 10-meter test (10MWT), The 4 staโ€ฆ Capturing Key MG-symptoms Using Smartphone Recordings. NCT06743490n/a2 sites๐Ÿ“ Leiden๐Ÿ“ Leiden Leiden University Medical Center Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART Cohort Study on Neuroimmune Diseases in the Reproductive Age NCT07653984n/a1 site๐Ÿ“ Guangzhou Third Affiliated Hospital, Sun Yat-Sen University Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites๐Ÿ“ Sioux Falls๐Ÿ“ Sydney Sanford Health Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. NCT06342544Phase 311 sites๐Ÿ“ Bordeaux๐Ÿ“ Garches๐Ÿ“ Lille Fondation Ophtalmologique Adolphe de Rothschild ยท Tests: immediate treatment with corticosteroids, addition of rituximab if recurrence A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy NCT06249438Phase 11 site๐Ÿ“ Shanghai RenJi Hospital ยท Tests: CD20/BCMA-directed CAR-T cells Myasthenia Gravis Foundation of America Global MG Patient Registry NCT06617741n/a1 site๐Ÿ“ Westborough Myasthenia Gravis Foundation of America A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis NCT07250750Phase 1, Phase 225 sites๐Ÿ“ Altamonte Springs๐Ÿ“ Boca Raton๐Ÿ“ Naples ImmunAbs Inc. ยท Tests: IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) NCT07249632Phase 31 site๐Ÿ“ Beijing RemeGen Co., Ltd. ยท Tests: Telitacicept, Placebo A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis NCT07465289Phase 37 sites๐Ÿ“ Columbus๐Ÿ“ Beijing๐Ÿ“ Nanchang UCB Biopharma SRL ยท Tests: Rozanolixizumab Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis NCT07146425n/a1 site๐Ÿ“ Shanghai Huashan Hospital Study of Ultomirisยฎ (Ravulizumab) Safety in Pregnancy NCT06312644n/a7 sites๐Ÿ“ Boston๐Ÿ“ Melbourne๐Ÿ“ Paris Alexion Pharmaceuticals, Inc. ยท Tests: Ultomiris Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System NCT04561557EARLY Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: CT103A cells, Cyclophosphamide and fludarabine Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases NCT07022197Phase 1, Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University General Hospital ยท Tests: BAFF-R CART A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders NCT06680037Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Ann Arbor๐Ÿ“ Omaha TG Therapeutics, Inc. ยท Tests: Azercabtagene zapreleucel (azer-cel) AXIS MG Patient Registry NCT07761026n/a1 site๐Ÿ“ Framingham Autoimmune Neurology Alliance Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. NCT07526493Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: Universal CD19 CAR-ฮณฮดT Cell Injection, Cyclophosphamide, Fludarabine Biomarkers in Autoimmune Disease of Nervous System NCT06502015n/a1 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: biomaker levels A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis NCT07463521Phase 315 sites๐Ÿ“ Scottsdale๐Ÿ“ O'Fallon๐Ÿ“ Amherst UCB Biopharma SRL ยท Tests: Rozanolixizumab, Placebo Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies NCT06941584n/a1 site๐Ÿ“ Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS ยท Tests: Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay, AIRE single gene sequencing, Molecular typโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy